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Polychlorinated biphenyls (PCBs) are   persistent 
lipophilic compounds that have bioaccumu-
lated and biomagnified within the human 
food chain (Agency for Toxic Substances and 
Disease Registry 2000; Givens et al. 2007), 
resulting in ubiquitous exposure for many 
populations. Consumption of contaminated 
fish is a primary route of human exposure, 
and such consumption has been associated 
with adverse reproductive effects (e.g., time to 
pregnancy, menstruation) (Buck Louis et al. 
2009; Mendola et al. 1997) and developmen-
tal effects (e.g., birth weight, birth defects, 
developmental delays) (Halldorsson et al. 
2008; Jacobson et al. 1985; Mendola et al. 
2005). A collective body of research relying 
on serum and plasma concentrations of PCBs 
in relation to reproductive and developmental 
outcomes corroborates earlier research relying 
on proxy exposures such as fish consumption, 
occupation, or residence. Specifically, prenatal 
PCBs have been associated with decrements in 
birth weight when measured in serum (Hertz-
Picciotto et al. 2005; Sonneborn et al. 2008) 
or plasma (Halldorsson et al. 2008).
PCBs readily cross the placenta (Jacobson 
et al. 1984), underscoring the importance of 
the in utero or prenatal exposure for the devel-
oping embryo and fetus. Recognizing this sen-
sitive window, investigators have attempted 
to quantify prenatal exposures by measuring 
PCBs in maternal blood obtained at some 
point during pregnancy (Hertz-Picciotto et al. 
2005), after delivery (Sonneborn et al. 2008), 
or using cord blood to represent prenatal expo-
sure (Tan et al. 2009). Other investigators have 
quantified PCBs in breast milk, given its high 
fat content coupled with the lipophilic nature 
of PCBs, as a measure of postnatal exposure 
for nursing infants (Patandin et al. 1998). 
Although the exact mechanism remains to be 
elucidated, PCBs are known to disrupt thy-
roid hormone signaling and other endocrine 
pathways critical to development that could 
lead to decreased in utero growth (Agency for 
Toxic Substances and Disease Registry 2000). 
In addition, growing evidence supports the 
manifestations of effects after exposures during 
earlier sensitive windows at later ages, such as 
at birth, during childhood, or in adulthood 
(Boisen et al. 2001; Skakkebaek et al. 2001). 
To a large extent, the timing of biospecimen 
collection for the quantification of PCB expo-
sure has been ignored, given their assumed 
stability in blood during pregnancy. Recent 
evidence suggests that timing may be impor-
tant, because concentrations decline from the 
preconception to postnatal sensitive windows 
(Bloom et al. 2007). If corroborated, effect 
sizes based on measurements later in pregnancy 
may be biased toward the null. To address 
this concern, we assessed the effect of PCB 
concentrations both before and shortly after 
conception in relation to birth weight and 
gestation. We further attempted to elucidate 
specific PCB congeners that may be associ-
ated with birth weight. To our knowledge, no 
previous studies have examined multiple PCB 
measurements during the pre- and periconcep-
tion sensitive windows of development or by 
purported biologic activity of congener group-
ings in relation to birth weight and gestation.
Materials and Methods
Study population. A cohort of women plan-
ning pregnancies was recruited from a larger 
population-based cohort of anglers who previ-
ously participated in a study focusing on fish 
consumption and health (Vena et al. 1996). 
In 1995 and 1996, 2,637 participating women 
were recontacted and mailed introductory 
letters followed by telephone follow-up to 
ascertain their pregnancy intentions and will-
ingness to participate in a study focusing on 
PCBs, time to pregnancy, and pregnancy out-
comes; 1,031 (39%) women were successfully 
screened, of whom 244 (24%) were eligible 
for participation. Eligibility criteria included 
age 18–34 years, no physician-diagnosed infer-
tility, and planning a pregnancy in the next 
6 months. Among the 244 eligible women, 
113 (46%) were recruited and enrolled into 
the cohort; another 14 were identified as 
already pregnant around enrollment and were 
excluded. Of the 99 remaining eligible women, 
20 withdrew during the 12 months of attempt-
ing pregnancy. Of the 79 women complet-
ing the study follow-up, 69 became pregnant 
within the time frame of the study, and 55 
(70%) of these pregnancies resulted in live 
births. Ten (13%) participants were unable 
to conceive after 12 menstrual cycles, and 14 
(18%) experienced pregnancy losses. Human 
subject approval was awarded for the study 
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Ba c k g r o u n d: Prenatal and postnatal polychlorinated biphenyl (PCBs) exposure has been 
  associated with decrements in fetal and infant growth and development, although exposures dur-
ing the preconception window have not been examined despite recent evidence suggesting that this 
window may correspond with the highest serum concentrations.
oBjectives: We assessed maternal serum PCB concentrations at two sensitive developmental win-
dows in relation to birth weight.
Me t h o d s : Serum samples were collected from 99 women as they began trying to become pregnant 
(preconception) and after a positive pregnancy test (prenatal); 52 (53%) women gave birth and rep-
resent the study cohort. Using daily diaries, women recorded sexual intercourse, menstruation, and 
home pregnancy test results until pregnant or up to 12 menstrual cycles with intercourse during the 
estimated fertile window. With gas chromatography with electron capture, 76 PCB congeners were 
quantified (nanograms per gram serum) and subsequently categorized by purported biologic activ-
ity. Serum PCBs were log-transformed and entered both as continuous and categorized exposures 
along with birth weight (grams) and covariates [smoking (yes/no), height (inches), and infant sex 
(male/female)] into linear regression. 
re s u l t s: A substantial reduction in birth weight (grams) was observed for women in the high-
est versus the lowest tertile of preconception antiestrogenic PCB concentration (β = –429.3 g, 
p = 0.038) even after adjusting for covariates (β = –470.8, p = 0.04).
co n c l u s i o n s: These data reflect the potential developmental toxicity of antiestrogenic PCBs, par-
ticularly during the sensitive preconception critical window among women with environmentally 
relevant chemical exposures, and underscore the importance of PCB congener–specific investigation.
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protocol by the Institutional Review Board for 
the School of Medicine & Biomedical Sciences 
at the University at Buffalo, State University of 
New York, and individual written consent was 
obtained from all women before data collection.
Data collection. Women completed base-
line interviews on discontinuing contraception 
and completed daily diaries about menstrua-
tion, sexual intercourse, home pregnancy test 
results, and lifestyle behaviors (e.g., cigarette 
use and alcohol consumption). Research 
nurses instructed women in the use of home 
pregnancy kits designed to detect 50 mIU 
of human chorionic gonadotropin (hCG) 
in urine. As a part of the standardized pro-
tocol, women were instructed to test their 
urine for pregnancy on the day of expected 
menses, given that women’s menstrual cycles 
differ in length, and then again 1 week later 
regardless of the results of the first test. We 
estimated gestational length as the number of 
days between the estimated date of concep-
tion and delivery date. Specifically, conception 
was estimated to have occurred 14 days before 
the first positive pregnancy test. Birth weights 
were reported by mothers after delivery.
Women provided nonfasting blood sam-
ples (10 mL) for the quantification of PCBs at 
baseline (preconception) on completion of the 
standardized interview and enrollment into the 
cohort during 1996–1998, after a positive preg-
nancy test [prenatal: median, 6 weeks gestation; 
interquartile range (IQR), 2 weeks], and after 
delivery (postnatal: median, 6 weeks postdeliv-
ery; IQR, 2 weeks). Among the 55 women who 
became pregnant, serum samples in sufficient 
amounts for toxicologic analysis were avail-
able for 50 women during the preconception 
period, 52 women in the prenatal period, and 
52 women in the postnatal period. Fifty-two 
(95%) children underwent a neurodevelopmen-
tal assessment at 2 years of age, and optional 
blood specimens were obtained for 19 (35%) 
children (Senn et al. 2005).
Toxicologic analysis. Maternal serum 
samples were analyzed by one toxicologic lab-
oratory for 76 congeners (64 single and 12 
dieluting congeners) as previously described 
(Bloom et al. 2007). Briefly, gas chroma-
tography with electron capture detection 
(GC-ECD) was used to analyze serum samples 
in batches of 10 with four additional qual-
ity control (QC) samples. These QC samples 
comprised one reagent blank, one serum 
blank, one sample containing sheep serum and 
15 calibration standards at known values, and 
one participant’s duplicate sample.
Children’s serum was analyzed for the 
quantification of 209 PCB congeners by high-
resolution gas chromatography/high-  resolution 
mass spectrometry (HRGC/HRMS) as per-
formed by AXYS Analytical Services, Ltd. 
(Sidney, British Columbia, Canada), using 
U.S. Environmental Protection Agency (EPA) 
method 1668A (U.S. EPA 2008). Briefly, 
serum is spiked with 13C-labeled surrogate 
standards before solvent extraction and instru-
mental analysis. Extracts are subject to chro-
matographic cleanup procedures. The quality 
assurance component included three controls: 
one reagent blank, one spiked reference blank, 
and one participant’s duplicate sample. This 
laboratory met the World Health Organization 
criteria for analysis of PCBs in human milk 
and plasma (Stephens et al. 1992).
All laboratory values were corrected only 
for recovery to minimize measurement error 
and to avoid potential biases associated with 
substitution of values below the limit of detec-
tion or the automatic adjustment for lipids 
(Schisterman et al. 2006; Whitcomb and 
Schisterman 2008). Therefore, all machine-read 
values were included in the analyses without 
substitution for values below the limit of detec-
tion, which differed by congener and batch.
Statistical analysis. PCB congeners were 
expressed in nanograms per gram of serum wet 
weight comparable with parts per billion. In an 
attempt to assess PCB mixtures in the context 
of our limited cohort size, we used an a priori 
classification scheme for grouping congeners by 
purported biologic activity (Cooke et al. 2001), 
given the absence of universally accepted 
groupings of congeners by biologic activity. 
We first summed all measured congeners into 
a simple total and then categorized them into 
estrogenic, antiestrogenic, and other congener 
groupings. The sum of estrogenic congeners 
included congeners 4_10, 5_8, 15_17, 18, 31, 
44, 47, 48, 52, 70, 99, 101, 136, 153, and 
188, whereas the sum of antiestrogenic con-
geners included congeners 77_110, 105, 114, 
126, 156_171, and 169 (underscores indi-
cate dielution). The other congener grouping 
Table 1. Maternal characteristics and associations with birth weight (n = 55).
Characteristic Value β SE
Education
Less than college 18 (33) Reference
College graduate or higher 37 (67) 120.4 183.4
Gravidity
Nulligravida 8 (15) Reference
Multigravida 47 (85) 140.6 215.9
Parity
Nulliparous 10 (18) Reference
Multiparous 45 (82) 173.8 225.8
Preconception cigarette use
No 38 (72) Reference
Yes 15 (28) –263.8 193.5
Infant sex
Male 29 (47) Reference
Female 26 (53) –250.5 175.4
Maternal age (years) 30 ± 2.3 6.9 38.3
Preconception BMI (kg/m2) 24 ± 4.8 5.7 16.7
Maternal height (inches) 65 ± 2.8 17.2 29.4
Preconception serum lipids (mg/dL) 4.2 ± 1.4 39.1 69.9
Prenatal serum lipids (mg/dL) 4.2 ± 1.5 94.9 56.8
Gestational age (days) 258 ± 14 6.3* 4.8
BMI, body mass index. Values are no. (%) or mean ± SD. Missing data were uniformly excluded from analyses. β-Values, 
SEs, and p-values were estimated using linear regression of characteristics on birth weight (grams).
*p < 0.001.
Table 2. Maternal serum PCB concentrations during sensitive windows.
Preconceptiona Prenatalb
Congener grouping (tertiles ng/g serum) Mean Median IQR Mean Median IQR
Total PCBs 5.6 5.3 5.0–6.2 4.7 4.5 3.8–5.5
Low 4.5 4.6 4.1–5.0 3.5 3.6 3.3–3.8
Medium 5.4 5.3 5.1–5.4 4.5 4.5 4.2–4.8
High 6.9 6.3 6.2–7.0 5.9 5.8 5.5–6.2
Antiestrogenic PCBs 0.22 0.20 0.15–0.23 0.13 0.11 0.09–0.15
Low 0.13 0.15 0.13–0.15 0.08 0.08 0.07–0.09
Medium 0.20 0.20 0.19–0.20 0.11 0.11 0.11–0.11
High 0.32 0.28 0.23–0.33 0.20 0.17 0.15–0.21
Estrogenic PCBs 2.3 2.2 2.1–2.4 1.9 1.9 1.6–2.2
Low 1.9 1.9 1.7–2.1 1.5 1.4 1.4–1.6
Medium 2.2 2.2 2.1–2.3 1.9 1.9 1.8–2.0
High 2.7 2.7 2.5–2.7 2.4 2.4 2.2–2.5
Other PCBs 3.1 2.9 2.6–3.4 2.6 2.6 2.1–3.1
Low 2.4 2.5 2.3–2.6 2.0 1.9 1.8–2.1
Medium 2.9 2.9 2.8–3.0 2.5 2.6 2.4–2.7
High 4.0 3.6 3.4–3.9 3.4 3.3 3.2–3.4
an = 50. bn = 52.Preconception PCB concentrations and birth weight
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comprised congeners 6, 7_9, 16_32, 19, 22, 
24_27, 25, 28, 33, 40, 42, 45, 50, 55, 59, 60, 
64, 66_95, 74, 81_87, 82, 94, 97, 118, 128, 
129, 132, 134, 135, 138, 141, 147, 149, 151, 
157_200, 163, 167, 170, 172, 174, 176, 177, 
179, 180, 181, 183, 185, 187, 189, 190, 194, 
195, 196_203, 205, and 206. PCB concentra-
tions were log transformed to meet the normal-
ity assumptions for our statistical models and 
also were categorized into tertiles.
We quantified total serum lipids (TL) 
using enzymatic methods as the function of 
total cholesterol (TC), free cholesterol (FC), 
triglycerides (TG), and phospholipids (PL) 
using the formula TL = 1.677 (TC – FC) + 
FC + TG + PL (Phillips et al. 1989). We did 
not automatically adjust serum PCB concen-
trations for lipids, given the causal assumption 
implicit in this approach (Schisterman et al. 
2005). Lipid adjustment implies that lipids are 
causally related to birth weight and exposure. 
However, we were unaware of any empirical 
evidence to support this strong assumption 
necessitating the use of unadjusted concentra-
tions in statistical models. Moreover, recent 
evidence suggests that such approaches intro-
duce a form of bias (Schisterman et al. 2005). 
Given the remaining controversy regarding 
how best to model serum lipids for nonfasting 
samples, we assessed maternal serum lipids as a 
covariate in the statistical models (although no 
relation was observed supporting our a priori 
decision). For the analyses comparing mater-
nal and children’s serum concentrations, we 
restricted the data to the 76 congeners com-
mon to both matrices and lipid-adjusted all 
concentrations, given that we were comparing 
different media with varying lipid concentra-
tions rather than health outcomes per se.
After inspection of the graphical displays 
of continuous exposure data and birth weight, 
we used various descriptive statistics to fully 
assess the quality of the data and to obtain 
measures of central tendency and dispersion. 
We used ordinary least squares (OLS) linear 
regression to identify determinants of birth 
weight (grams) and gestation (days), including 
the relation between maternal PCB concentra-
tions and birth weight. We conducted sepa-
rate analyses for PCB concentrations as both 
continuous natural log–transformed (nano-
grams per gram serum) and categorized (ter-
tiles) exposures. Preconception and prenatal 
PCBs were modeled separately for each PCB 
grouping (i.e., total, estrogenic, antiestrogenic, 
and other congeners). Postnatal PCB con-
centrations were not analyzed in relation to 
birth weight, given that they were quantified 
at a median of 6 weeks after delivery. Hence, 
we could not support the temporal ordering 
between PCB exposure and outcome.
We inspected OLS regression residuals to 
verify that a linear model was appropriate. 
Given our limited cohort size, we adjusted 
only for covariates relevant for the exposures 
and outcome (i.e., maternal preconception 
cigarette smoking, height, serum lipids, and 
infant’s sex) and retained those that altered the 
exposure’s coefficient by > 15%. We modeled 
cigarette smoking as a dichotomous variable 
and also in categories based on the observed 
distribution (0, 1–5, and > 5 cigarettes per 
day) and found little difference in the esti-
mated values of the parameter associated with 
the exposure. Thus, we chose the dichotomous 
categorization to support a more parsimoni-
ous model in light of our limited sample size. 
A priori, we decided not to adjust for gesta-
tional age when estimating PCB effects on 
birth weight because gestational age is in the 
causal pathway and not a confounder per se 
(Weinberg 1993). Such an adjustment has 
been empirically demonstrated to introduce 
bias (Schisterman et al. 2009). We explored 
a potential interaction between infant sex 
and PCB concentrations, in response to ear-
lier reports suggesting male susceptibility for 
decrements in birth weight (Sonneborn et al. 
2008), by including an interaction term in 
the adjusted models and assessing the p-value 
obtained by the Wald chi-square test. Lastly, 
we assessed maternal serum PCB concentra-
tions before, during, and after pregnancy in 
relation to children’s serum concentrations at 
2 years of age along with duration of breast-
feeding to estimate the variation explained by 
each. The percentage of explained variation 
for each sensitive window and breast-feed-
ing duration in relation to children’s serum 
concentration was calculated by dividing each 
model coefficient’s type III sums of squares 
by the total model type III sum of squares. 
For example, the percentage of variation 
explained by maternal preconception concen-
trations was estimated as the preconception 
PCB coefficient sum of squares (0.15) divided 
by the total model sum of squares (0.679) = 
22%. Children who were not breast-fed were 
assigned a breast-feeding duration of 0 days.
Results
The cohort comprised white married women 
who were largely college educated (67%) and 
nonsmokers at the time of cohort commence-
ment (72%) (Table 1). Mean ± SD birth 
weight and gestational age for the cohort’s 
infants were 3,500 ± 580 g and 258 ± 14 days, 
respectively. To this end, 6.0% of infants 
were classified as having a low birth weight 
(< 2,500 g), and 9.1% of infants were clas-
sified as preterm (gestational age < 245 days 
from the date of conception). Other than ges-
tational age, no other covariates were signifi-
cantly associated with birth weight, although 
patterns for female sex and cigarette smoking 
were in the expected direction: Female infants 
and those born to mothers who reported 
smoking before conception had lower birth 
weights than their respective counterparts.
Mean total PCB concentrations were 
higher at baseline (preconception) than dur-
ing the prenatal period (i.e., 5.6 and 4.7 ng/g 
serum, respectively) (Table 2). The relation 
between preconception PCB concentra-
tions and birth weight varied by PCB group-
ing, with antiestrogenic PCBs conferring an 
approximately 471-g reduction in birth weight 
for women in the highest versus lowest tertile 
of exposure when adjusting for study cova-
riates (p = 0.048), but no such decrement 
for estrogenic PCBs (Table 3). This pattern 
Table 3. Maternal serum PCB concentrations and birth weight [β (95% CI)].
Preconception Prenatal
PCB concentration (tertiles ng/g serum) Unadjusted Adjusteda Unadjusted Adjusteda
Total PCBs
Medium –309.3 (–701.9 to 83.4) –306.8 (–696.9 to 83.3) –105.0 (–497.0 to 286.9) –119.1 (–512.0 to 273.9)
High –237.6 (–630.2 to 155.1) –205.5 (–618.1 to 207.0) –120.8 (–505.5 to 263.9) –140.9 (–543.1 to 261.3)
Antiestrogenic PCBs
Medium 2.1 (–375.9 to 386.0) –11.0 (–391.1 to 369.1) 89.3 (–290.0 to 468.7) 58.9 (–324.1 to 441.9)
High –429.3 (–807.2 to –51.4)* –470.8 (–890.2 to –51.3)* –248.9 (–628.2 to 130.5) –260.5 (–667.4 to 146.5)
Estrogenic PCBs
Medium 167.6 (–225.7 to 560.9) 281.6 (–108.8 to 672.1) 65.3 (–320.8 to 451.5) 118.3 (–276.3 to 513.0)
High 15.0 (–399.7 to 429.6) 34.7 (–373.0 to 442.4) 21.4 (–372.0 to 414.8) 3.2 (–420.3 to 426.6)
Other PCBs
Medium –150.2 (–555.1 to 254.7) –125.4 (–529.1 to 278.4) 1.2 (–385.8 to 388.3) –51.1 (–453.1 to 350.8)
High –255.5 (–645.3 to 134.2) –235.6 (–636.1 to 165.0) –220.0 (–599.9 to 159.9) –200.0 (–591.2 to 191.1)
CI, confidence interval. Low tertiles were used as the referent category in linear regression models. The valid sample number is 50 for the preconception models and 52 for the 
  prenatal models.
aAdjusted for maternal height, maternal preconception smoking (yes/no), and infant’s sex. *p < 0.05. Murphy et al.
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remained when assessing prenatal concentra-
tions in tertiles, although the results did not 
achieve significance. When we assessed total 
PCBs or PCB groupings as continuous log-
transformed exposures, we found no signifi-
cant associations; however, all β-coefficients 
were negative (total PCBs: β = –400, p = 0.29; 
antiestrogenic PCBs: β = –100, p = 0.40; 
estrogenic PCBs: β = –700, p = 0.16; other 
PCBs: β = –300, p = 0.39).
In an attempt to delineate which anti-
estrogenic PCB congeners may be driving the 
reduction in birth weight, we analyzed each 
congener (congeners 77_110, 105, 114, 126, 
156_171, 169) in relation to birth weight. We 
observed no significant associations between 
specific congeners and birth weight, although 
most associations were negative (data not 
shown). However, preconception PCB-105 
concentration was associated with the largest 
individual reduction in birth weight when 
comparing women in the highest versus low-
est tertile (β = –370 g, p = 0.075) or in its 
continuous form (β = –380, p = 0.054, for 
unit change in nanograms per gram PCB on 
the natural log scale). We explored a pos-
sible interaction for PCBs (continuous and 
by grouping) and infant sex but observed no 
significant effects in either the unadjusted or 
adjusted models. In a secondary analysis, we 
examined PCB concentrations in relation to 
gestational length in days from conception 
without observing an association irrespective 
of PCB groupings (third vs. first tertile: total 
preconception PCBs, unadjusted β = 0.87, 
p = 0.84; total prenatal PCBs, unadjusted 
β = 0.5, p = 0.90). Results were largely 
unchanged after adjustment for maternal age 
and cigarette smoking.
Last, we explored maternal serum con-
centrations at sensitive windows and duration 
of breast-feeding in relation to the children’s 
serum concentrations at 2 years of age to 
estimate the correlation of maternal–child 
serum concentrations, as well as the varia-
tion explained in children’s concentrations 
by maternal concentrations at varying sensi-
tive windows. Table 4 presents four models, 
starting with preconception and adding each 
successive sensitive window (prenatal and post-
natal), with model 4 including all three sen-
sitive windows plus breast-feeding duration. 
Maternal preconception PCB concentrations 
and breast-feeding duration explained 15–22% 
and 32%, respectively, of children’s concen-
trations at age 2 years. Importantly, 56% of 
children’s PCB concentrations were explained 
by maternal serum concentrations during the 
preconception, prenatal, and postnatal sensitive 
windows and duration of breast-feeding. The 
correlation coefficients for children’s PCB con-
centrations and maternal PCB concentrations 
were 0.47 (preconception), 0.16 (prenatal), 
and 0.33 (postnatal). We observed a correla-
tion of 0.53 for duration of breast-feeding and 
children’s PCB concentrations.
Discussion
In this population-based prospective cohort 
study with preconception enrollment of 
women, three important findings emerge that 
add to the evolving body of evidence suggest-
ing possible developmental toxicity of PCBs, 
particularly those purported to have anties-
trogenic activity. First, we observed a large 
reduction (~ 470 g) in birth weight for anti-
estrogenic PCBs during the preconception 
window, a time period unaffected by physi-
ologic changes associated with pregnancy, 
including those that precede a woman’s rec-
ognition of pregnancy. The magnitude of 
effect is considerably more than that reported 
for cigarette smoking (~ 55–189 g reduc-
tion) (Cliver et al. 1995), underscoring its 
importance for public health. Furthermore, 
we observed no significant reduction in ges-
tational age in relation to PCB groupings or 
concentrations despite having a valid esti-
mate of conception. This finding suggests that 
the reduction in birth weight is not medi-
ated through gestation, but instead through a 
pathway directly affecting fetal growth.
A second key finding is the importance 
of congener groupings when assessing PCBs 
and human development as measured by birth 
weight. Estrogenic PCBs were not negatively 
associated with birth weight in our cohort and 
may explain, in part, the equivocal findings 
across studies, particularly those that do not dif-
ferentiate their exposures by purported biologic 
activity or that rely on simple sums of PCBs 
or select congeners (Ribas-Fito et al. 2002; 
Wolff et al. 2007). Last, our findings provide 
empirical support that maternal exposures affect 
children’s exposures regardless of breast-feeding. 
As previously stated, duration of breast-feeding 
explained a considerable percentage, but not all, 
of children’s serum concentrations.
Despite increasing recognition about crit-
ical or sensitive windows of human devel-
opment (Chapin et al. 2004; Johnson et al. 
2006; Louis et al. 2008), we are unaware 
of other prospective cohort studies enroll-
ing women/couples before conception for the 
quantification of PCBs. Thus, it is difficult 
to fully interpret our data relative to others’ 
work. Prior investigators have assessed mater-
nal PCB concentrations in relation to birth 
weight, but typically have relied on blood col-
lected at varying times during pregnancy or at 
delivery (Hertz-Picciotto et al. 2005; Karmaus 
and Zhu 2004; Sonneborn et al. 2008) or 
on cord blood or breast milk (Patandin et al. 
1998; Tan et al. 2009). Collectively, past 
research suggests a decrement of 100–300 g in 
birth weight for a subset of quantified PCBs 
in serum (Hertz-Picciotto et al. 2005). Our 
effect is larger for the antiestrogenic PCBs 
when quantified before conception, although 
the effect remains apparent during early preg-
nancy. A recent study using data from this 
cohort reported a decline in serum concentra-
tion from preconception to postnatal period 
(Bloom et al. 2007), suggesting the impor-
tance of timing biospecimen collection for 
assessing developmental toxicity. However, 
corroboration of these findings is needed to 
better inform investigators regarding when 
(and how often) to collect maternal biospeci-
mens when assessing developmental toxicity.
We are unaware of research efforts that 
have quantified PCBs by purported biologic 
activity or that have focused on antiestrogenic 
PCBs, more specifically, in relation to birth 
weight, possibly given the limited number 
of congeners selected in prior research or the 
reliance on simple sums of select congeners 
(Hertz-Picciotto et al. 2005; Patandin et al. 
1998; Sonneborn et al. 2008; Tan et al. 2009). 
Regardless, the available evidence suggests an 
adverse relation between maternal PCBs and 
birth weight (Halldorsson et al. 2008; Hertz-
Picciotto et al. 2005; Karmaus and Zhu 2004; 
Patandin et al. 1998; Sonneborn et al. 2008). 
Previous studies reporting reductions in birth 
weight have generally reported PCB concentra-
tions relatively similar to ours, although often 
with fewer measured congeners. For exam-
ple, median total PCB concentrations have 
ranged from 1.11 µg/L plasma (Halldorsson 
et al. 2008) or 2.0 µg/L plasma (Patandin et al. 
1998) to 5–8 µg/L wet weight serum (Karmaus 
and Zhu 2004; Sonneborn et al. 2008). Our 
pregnancy cohort had a range of PCB concen-
trations, although a median total prenatal PCB 
concentration of 4.5 (range, 3.8–5.5) ng/g 
serum, which is comparable with the value 
reported by the U.S. Collaborative Perinatal 
Table 4. Variation in children’s serum PCB concentrations at 2 years of age explained by maternal PCB 
concentrations during sensitive windows (n = 19).
Maternal PCB concentration (ng/g lipid) Model R2
Model 1: preconception PCBs 0.22
Explained variation  22%
Model 2: preconception PCBs + prenatal PCBs 0.26
Explained variation 25% 6%
Model 3: preconception PCBs + prenatal PCBs + postnatal PCBs 0.28
Explained variation 20% 8% 2%
Model 4: preconception PCBs + prenatal PCBs + postnatal PCBs + breast-feeding duration 0.56
Explained variation  15% 2% < 1% 32%Preconception PCB concentrations and birth weight
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Project [4.4 (3.3–6.1) µg/L serum (Longnecker 
et al. 1999)], assuming nanograms per gram 
are comparable with micrograms per liter, with 
both representing parts per billion.
Estrogenic PCB congeners may disrupt 
endocrine activity by competitive binding with 
estrogenic receptors or by disrupting enzymes 
critical to estrogenic processes, whereas anties-
trogenic PCB congeners may inhibit the effects 
of endogenous estrogens (Cooke et al. 2001; 
Kester et al. 2000). Furthermore, estrogens 
in pregnancy are associated with increased 
birth weight (Kaijser et al. 2000; Nagata et al. 
2006), so PCB congeners with purported anti-
estrogenic bioactivity may disrupt estrogenic 
pathways, potentially leading to a decrease in 
birth weight. In addition, antiestrogenic con-
geners, such as PCB-105, have been implicated 
in thyroid-mediated effects due to high affinity 
for thyroid hormone–binding proteins, leading 
to disruptions in thyroid hormone signaling 
(Crofton et al. 2005), which may also disrupt 
growth and development (Sahu et al. 2009).
The absence of prior research with lon-
gitudinal measurement of PCBs during the 
preconception sensitive window coupled with 
quantification in children limits our ability 
to fully interpret our estimated explained 
variation in children’s serum concentrations 
relative to mothers’ concentrations during sen-
sitive windows of development. The plausi-
bility of the preconception window has been 
noted for other environmental exposures, such 
as the Dutch famine. Specifically, offspring 
whose mothers were affected by undernutri-
tion around the time of conception were more 
likely to have shorter gestations than were 
offspring whose mothers were not affected 
(38.6 vs. 39.0 gestational weeks, respectively; 
p < 0.0001) and also were more likely to have 
coronary heart disease and obesity as adults, 
underscoring the importance of the pre- and 
periconception window for human develop-
ment (Painter et al. 2005; Rayco-Solon et al. 
2005). Previous authors have assessed breast-
feeding in relation to children’s exposures and 
generally report higher levels among breast-fed 
children (Jacobson et al. 1989; Lanting et al. 
1998). We observed a similar finding, with 
breast-fed children having a higher mean ± SD 
PCB concentration at 2 years of age compared 
with formula-fed children (1.83 ± 1.6 ng/g 
and 0.41 ± 0.2 ng/g, respectively). Combined, 
these data support breast-feeding as a postnatal 
route of PCB exposure for nursing infants.
To our knowledge, only one prior study 
has modeled infant PCB concentrations as a 
function of maternal PCB concentrations at 
delivery or postnatally. Ayotte et al. (2003) 
analyzed maternal plasma concentrations 
of PCB-153 approximately at delivery and 
breast-feeding duration in relation to infant 
concentrations at age 6 months and reported 
that the model explained 66% of variation in 
infant PCB-153 plasma concentration. In our 
cohort, maternal preconception PCB con-
centrations explained the highest variation 
in children’s concentrations (15%), followed 
by prenatal (2%) and postnatal (<  0.1%) 
PCB concentrations. Breast-feeding duration 
increased the total explained variation to 50%, 
suggesting that maternal exposures account 
for half of children’s exposure at 2 years of 
age. Our estimate is lower than that reported 
by Ayotte et al. (2003) and may reflect the 
difference in age when children’s concentra-
tions were quantified or the choice of PCB 
congener(s) analyzed. Because children in our 
cohort were approximately 24 months of age 
when PCB concentrations were quantified, 
other environmental sources may contribute 
to their concentrations, particularly diet or 
play. In addition, we recognize the impreci-
sion in PCB concentrations particularly at 
lower limits given our use of GC-ECD for 
quantification of maternal serum, although 
we were able to use the HRGC/HRMS for 
quantifying children’s serum.
Several important limitations warrant 
cautious interpretation of the findings until 
larger prospective studies with longitudinal 
measurement of exposures during sensitive 
windows are available. Despite its limited size, 
the cohort was sufficiently powered to detect 
large differences in birth weight, which are 
at least twice the effect typically observed for 
cigarette smoking. However, we had limited 
power to assess other potential covariates or 
even a possible interaction with sex, which is 
concerning given that PCBs were previously 
associated with reduced secondary sex ratios or 
the number of male and female births in this 
cohort (Taylor et al. 2007). In another study, 
the association between maternal PCB con-
centrations and infant birth weight differed 
between male and female infants (Sonneborn 
et al. 2008). We were underpowered to assess 
the relation between daily rate of change in 
PCBs and birth weight, although we did 
assess changes in women’s tertile rankings 
across sensitive windows. The percentages of 
women remaining in the same tertile for pre-
conception and prenatal PCB concentrations 
were highest for antiestrogenic PCBs (58%), 
followed by other (47%), total (44%), and 
estrogenic (37%) PCBs. We did not have any 
other measures of birth size, such as length or 
head or abdominal circumferences, which pre-
vented us from assessing the proportionality of 
infants. We did have an excellent estimate of 
conception, given the longitudinal capture of 
menstruation, sexual intercourse, and hCG-
confirmed pregnancy. Other study limitations 
include maternal self-reported information 
on birth weight and the potential for resid-
ual confounding by cigarette smoking during 
pregnancy. However, we expect that accuracy 
of maternal reporting of birth weight is not 
related to PCB concentrations and therefore 
may introduce error but not bias per se. We 
recognize the potential for selection bias but 
did not have exposure data on women not 
participating to empirically assess its potential 
effect. Because women were unaware of their 
PCB concentrations, we assume that partici-
pation was not systematically associated with 
PCB exposure.
As the literature continues to evolve in 
support of an association between PCB expo-
sures during sensitive windows of fetal growth 
and development as measured by birth weight, 
it is essential that mechanistic research be 
conducted to better inform how best to pro-
tect vulnerable subgroups of the population. 
Determining whether and how such mecha-
nisms disproportionately affect males (or 
females) remains to be established.
Conclusions
Our prospective cohort study with longitu-
dinal measurement of maternal PCBs under-
scores the preconception interval as a sensitive 
window for human development, and the 
importance of quantifying a mixture of PCBs 
by purported biologic activity. Our findings 
underscore that preconception maternal expo-
sures at environmentally relevant concentra-
tions are adversely associated with fetal growth 
as approximated by birth weight and serve as 
a route of exposure for children along with 
breast-feeding.
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